Results 81 to 90 of about 17,579 (227)
Synthesis and evaluation of novel potent HCV NS5A inhibitors [PDF]
Bioorganic & Medicinal Chemistry Letters, 2012 Judicious modifications to the structure of the previously reported HCV NS5A inhibitor 1, resulted in more potent anti-HCV compounds with similar and in some cases improved toxicity profiles. The synthesis of 19 new NS5A inhibitors is reported along with their ability to block HCV replication in an HCV 1b replicon system.
Hongwang, Zhang +10 more
openaire +2 more sources
Electrosynthesis of Bioactive Chemicals, From Ions to Pharmaceuticals
Advanced Functional Materials, Volume 36, Issue 16, 23 February 2026.This review discusses recent advances in electrosynthesis for biomedical and pharmaceutical applications. It covers key electrochemical materials enabling precise delivery of ions and small molecules for cellular modulation and disease treatment, alongside catalytic systems for pharmaceutical synthesis.
Gwangbin Lee +4 more
wiley +1 more source
Partly 5` Untranslated Region (5` UTR)-Based Phylogenetic Analysis of Three Hepatitis C Virus Isolates From Jakarta, Indonesia: a Preliminary Study [PDF]
, 2014 Currently, we reported results of a nested PCR assay specific 5` UTR region of HCV genome that showed three different patterns of DNA fragments (single expected specific DNA band, single DNA band higher in size than an expected band, and multiple DNA ...
Rosilawati, M. L. (Maria) +1 more
core +2 more sources
In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug Transporters
The Journal of Clinical Pharmacology, Volume 66, Issue 2, February 2026.Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug candidate for the treatment of chronic hepatitis C virus infection. Potential drug–drug interactions (DDIs) of bemnifosbuvir as a substrate or perpetrator with regard to ATP‐binding cassette (ABC) and solute carrier (SLC) transporters were evaluated in vitro and in clinical studies ...
Xiao‐Jian Zhou +9 more
wiley +1 more source
PLoS Pathogens, 2008 Persistent infection with the hepatitis C virus (HCV) is a major risk factor for the development of liver cirrhosis and hepatocellular carcinoma. With an estimated about 3% of the world population infected with this virus, the lack of a prophylactic ...
Nicole Appel +8 more
doaj +1 more source
Infectious agents in atherosclerotic cardiovascular diseases through oxidative stress [PDF]
, 2017 Accumulating evidence demonstrates that vascular oxidative stress is a critical feature of atherosclerotic process, potentially triggered by several infectious agents that are considered as risk co-factors for the atherosclerotic cardiovascular diseases (
Di Pietro, M +4 more
core +2 more sources
Ubiquitination dynamics in human tumour viruses: Viral infection, oncogenesis and antiviral therapy
The FEBS Journal, Volume 293, Issue 2, Page 325-347, January 2026.The ubiquitin system is essential for cellular homeostasis and regulates many processes. Viruses, including oncogenic ones, exploit or evade this system to survive and replicate. This review explores how human tumour viruses manipulate the ubiquitination system to complete their life cycle, evade immunity and promote cancer.
Oscar Trejo‐Cerro +2 more
wiley +1 more source
Resistance Patterns Associated with HCV NS5A Inhibitors Provide Limited Insight into Drug Binding
Viruses, 2014 Direct-acting antivirals (DAAs) have significantly improved the treatment of infection with the hepatitis C virus. A promising class of novel antiviral agents targets the HCV NS5A protein.
Moheshwarnath Issur, Matthias Götte
doaj +1 more source
Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes [PDF]
ACS Medicinal Chemistry Letters, 2011 The iminothiazolidinone BMS-858 (2) was identified as a specific inhibitor of HCV replication in a genotype 1b replicon assay via a high-throughput screening campaign. A more potent analogue, BMS-824 (18), was used in resistance mapping studies, which revealed that inhibitory activity was related to disrupting the function of the HCV nonstructural ...
Jeffrey L, Romine +14 more
openaire +2 more sources
Journal of Cellular and Molecular Medicine, Volume 30, Issue 1, January 2026.ABSTRACT Hepatitis B and C viruses (HBV and HCV) remain among the leading causes of liver disease worldwide. Current antiviral drugs, such as nucleotide analogues (NAs), can reduce the replication of new HBV and HCV infections but cannot completely eliminate chronic infections.
Meng‐Fan Li +3 more
wiley +1 more source